Does the prevalence of nasal polyps increase in patients using statins?

Basit Öğe Kaydı
dc.authorid0000-0003-2541-4675
dc.authorid0000-0002-9339-8331
dc.authorid0000-0002-5078-2958
dc.authorid0000-0002-8877-3520
dc.authorid0000-0002-9205-5708
dc.contributor.authorYılmaz, Fahrettin
dc.contributor.authorGündüz, Hüseyin
dc.contributor.authorArınç, Hüseyin
dc.contributor.authorTalay, Fahrettin
dc.contributor.authorÖzyıldırım, Serhan
dc.contributor.authorAkyürek, Fatma
dc.contributor.authorUyan, Cihangir
dc.date.accessioned2021-06-23T19:19:43Z
dc.date.available2021-06-23T19:19:43Z
dc.date.issued2007
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractSeveral statins inhibit T-helper I development and induce T-helper 2 polarization and production of T-helper 2 cytokines that promote the activation and chemotaxis of eosinophils. Whether statins promote the development of nasal polyps has so far been uncertain. No studies have evaluated the frequency of the development of nasal polyps in patients using statins. To better define the relationship of statin use to the presence of nasal polyps, the investigators explored the frequency of the development of nasal polyps in patients who were using statins. A total of 200 patients who were using statins and 200 who were not using statins (400 cases) were investigated. All patients were examined for nasal polyps by anterior rhinoscopy or investigation with a fiber-optic endoscope. In addition, immunoglobulin E levels were measured, a skin prick test was performed, and the results from the 2 groups were compared. Nasal polyps were detected in 4 subjects who were using statins, whereas 5 nasal polyps were found in the control group; differences between the 2 groups were statistically insignificant (P >.05). When the atopy status of the 2 groups was compared, prick test positivity and serum immunoglobulin E levels were found to be 15% and 44 +/- 31 IU/mL in the statin group and 19% and 68 +/- 23 IU/mL in the control group (P >.05). These results show that nasal polyposis is a multifactorial disease with several different causes; however, the frequency of the development of nasal polyps does not increase in patients who use statins.en_US
dc.identifier.doi10.1007/BF02877780
dc.identifier.endpage1339en_US
dc.identifier.issn0741-238X
dc.identifier.issn1865-8652
dc.identifier.issue6en_US
dc.identifier.pmid18165216en_US
dc.identifier.scopus2-s2.0-41749092111en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1330en_US
dc.identifier.urihttps://doi.org/10.1007/BF02877780
dc.identifier.urihttps://hdl.handle.net/20.500.12491/5992
dc.identifier.volume24en_US
dc.identifier.wosWOS:000252845200018en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGündüz, Hüseyin
dc.institutionauthorYılmaz, Fahrettin
dc.institutionauthorArınç, Hüseyin
dc.institutionauthorTalay, Fahrettin
dc.institutionauthorÖzyıldırım, Serhan
dc.institutionauthorAkyürek, Fatma
dc.institutionauthorUyan, Cihangir
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAdvances In Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNasal Polypen_US
dc.subjectStatinen_US
dc.subjectFrequencyen_US
dc.titleDoes the prevalence of nasal polyps increase in patients using statins?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
fahrettin-yilmaz.pdf
Boyut:
215.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu